Cannabidiol-2′,6′-Dimethyl Ether, a Cannabidiol Derivative, Is a Highly Potent and Selective 15-Lipoxygenase Inhibitor

@article{Takeda2009Cannabidiol26DimethylEA,
  title={Cannabidiol-2′,6′-Dimethyl Ether, a Cannabidiol Derivative, Is a Highly Potent and Selective 15-Lipoxygenase Inhibitor},
  author={Shuso Takeda and Noriyuki Usami and Ikuo Yamamoto and Kazuhito Watanabe},
  journal={Drug Metabolism and Disposition},
  year={2009},
  volume={37},
  pages={1733 - 1737}
}
The inhibitory effect of nordihydroguaiaretic acid (NDGA) (a nonselective lipoxygenase (LOX) inhibitor)-mediated 15-LOX inhibition has been reported to be affected by modification of its catechol ring, such as methylation of the hydroxyl group. Cannabidiol (CBD), one of the major components of marijuana, is known to inhibit LOX activity. Based on the phenomenon observed in NDGA, we investigated whether or not methylation of CBD affects its inhibitory potential against 15-LOX, because CBD… 

Tables from this paper

Cannabidiol-2',6'-dimethyl ether as an effective protector of 15-lipoxygenase-mediated low-density lipoprotein oxidation in vitro.

The results obtained demonstrate that CBDD is a potent and selective inhibitor of ox-LDL formation generated by the 15-LOX pathway, establishing CBDD as both an important experimental tool for characterizing 15- LOX-mediated ox- LDL formation, and as a potentially useful therapeutic agent for treatment of atherosclerosis.

Δ9-tetrahydrocannabinol and its major metabolite Δ9-tetrahydrocannabinol-11-oic acid as 15-lipoxygenase inhibitors.

It is suggested that Δ (9) -THC can abrogate atherosclerosis via direct inhibition of 15-LOX, and that Δ(9)-THC-11-oic acid is shown to be an "active metabolite" of Δ( 9) - THC in this case.

Structural requirements for potent direct inhibition of human cytochrome P450 1A1 by cannabidiol: role of pentylresorcinol moiety.

The results suggest that the pentylresorcinol structure in CBD may have structurally important roles in direct CYP1A1 inhibition, although the whole structure of CBD is required for overall inhibition.

O-Methyl Phytocannabinoids: Semi-synthesis, Analysis in Cannabis Flowerheads, and Biological Activity.

O-Methylation of alkyl phytocannabinoids does not significantly change the activity on peroxisome proliferator-activated receptors in contrast to what was reported for phenethyl analogues.

Cannabidiol-2',6'-dimethyl ether stimulates body weight gain in apolipoprotein E-deficient BALB/c. KOR/Stm Slc-Apoe(shl) mice.

The effects of CBDD on body weight changes in mice were focused on, and it was demonstrated that it stimulated body weight gain in apolipoprotein E (ApoE)-deficient BALB/c.

(--)-Xanthatin selectively induces GADD45γ and stimulates caspase-independent cell death in human breast cancer MDA-MB-231 cells.

The results presented here suggest the novel possibility that (--)-xanthatin may have therapeutic value as a selective inducer of GADD45γ in human cancer cells, in particular in FTI-resistant aggressive breast cancers.

Pharmacological Properties of the Plant-Derived Natural products Cannabinoids and Implications for Cardiovascular Health.

Clinical and experimental evidence linking phytocannabinoids to CV disease is critically discussed, attempting at explaining some controversies and suggesting the direction for future studies.

Down-regulation of cyclooxygenase-2 (COX-2) by cannabidiolic acid in human breast cancer cells.

Results obtained here demonstrated that cannabidiolic acid had dual inhibitory effects on COX-2 through down-regulation and enzyme inhibition, and CBDA may possess the ability to suppress genes that are positively involved in the metastasis of cancer cells in vitro.

An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol

This review provides an overview of the chemical structure of natural and synthetic CBD derivatives including the molecular targets associated with these compounds.

References

SHOWING 1-10 OF 50 REFERENCES

Cannabidiolic Acid as a Selective Cyclooxygenase-2 Inhibitory Component in Cannabis

The lines of evidence in this study suggest that naturally occurring CBDA in cannabis is a selective inhibitor for COX-2.

Inhibitory effect of cannabidiol hydroxy-quinone, an oxidative product of cannabidiol, on the hepatic microsomal drug-metabolizing enzymes of mice.

The results indicate that CBDHQ, which is an oxidation product of CBD, inhibits the hepatic microsomal drug-metabolizing enzymes through the decrease of cytochrome P-450 content.

6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist.

Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator.

Cannabidiol-hydroxyquinone formation may be the penultimate oxidative step involved in CBD-mediated modification and inactivation of P450 3A11, and reduced glutathione was used as a trapping agent for possible electrophilic metabolites.

In vivo and in vitro metabolism of cannabidiol monomethyl ether and cannabidiol dimethyl ether in the guinea pig: on the formation mechanism of cannabielsoin-type metabolite from cannabidiol.

Results indicate that 1S,2R-epoxide are formed from CBD, CBDM and CBDD and that the epoxides are quickly converted to elsoin-type metabolites in the cases of CBD and CBDM.

Cannabielsoin as a new metabolite of cannabidiol in mammals

Lipoxygenase interactions with natural flavonoid, quercetin, reveal a complex with protocatechuic acid in its X‐ray structure at 2.1 Å resolution

Structural analysis reveals that quercetin entrapped within LOX undergoes degradation, and the resulting compound has been identified by X‐ray analysis as protocatechuic acid (3,4‐dihydroxybenzoic acid) positioned near the iron site.

Inhibition of 15-lipoxygenases by flavonoids: structure-activity relations and mode of action.

INHIBITION OF UDP-GLUCURONOSYLTRANSFERASE 2B7-CATALYZED MORPHINE GLUCURONIDATION BY KETOCONAZOLE: DUAL MECHANISMS INVOLVING A NOVEL NONCOMPETITIVE MODE

Results suggest that 1) metabolism of ketoconazole by P450 is not required for inhibition of UGT2B7-catalyzed morphine glucuronidation; and 2) this drug exerts its inhibitory effect on morphine UGT by novel mechanisms involving competitive and noncompetitive inhibition.